Distinguished in Graft Versus Host Disease (GvHD)

Ronjon K. Chakraverty

Oxford, ENG, GB 
Distinguished in Graft Versus Host Disease (GvHD)
Oxford, ENG, GB 
OverviewLocationsClinical Research

Overview

Ronjon Chakraverty practices in Oxford, United Kingdom. Chakraverty is rated as a Distinguished expert by MediFind in the treatment of Graft Versus Host Disease (GvHD). Their top areas of expertise are Graft Versus Host Disease (GvHD), Primary Immunodeficiency (PID), Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Graft.

Their clinical research consists of co-authoring 59 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 21 articles and participated in 1 clinical trial in the study of Graft Versus Host Disease (GvHD).

Locations

Oxford, ENG, United Kingdom
Other Locations
Birmingham, ENG, United Kingdom
London, ENG, United Kingdom
Burton, WLS, United Kingdom
Loughborough, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Multicenter Randomized Phase II Study to Evaluate the Efficacy of Prophylactic Transfer of CD4 Lymphocytes After T-cell Depleted Reduced Intensity HLA-Identical Sibling Transplantation for Haematological Cancers
Multicenter Randomized Phase II Study to Evaluate the Efficacy of Prophylactic Transfer of CD4 Lymphocytes After T-cell Depleted Reduced Intensity HLA-Identical Sibling Transplantation for Haematological Cancers
Enrollment Status: Unknown
Publish Date: February 12, 2019
Intervention Type: Other
Study Drug: CD4 Donor Lymphocytes
Study Phase: Phase 2

59 Total Publications

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chakraverty's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile